Quantum Biopharma (QNTM) Accounts Payables (2018 - 2025)

Quantum Biopharma has disclosed Accounts Payables across 8 years of filings, most recently posting $2.0 million for Q4 2025.

• Accounts Payables for Q4 2025 came in at $2.0 million, down 39.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 million (down 39.11% YoY), and the FY2025 annual result was $2.0 million, down 39.11% from the prior year.
• Accounts Payables came in at $2.0 million for Q4 2025 at Quantum Biopharma, down from $3.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $7.5 million in Q4 2021 to a low of $2.0 million in Q4 2025.
• The 5-year median for Accounts Payables is $4.2 million (2023), against an average of $4.8 million.
• Across the five-year window, Accounts Payables soared 102.99% in 2021 and sank 40.99% in 2023, its largest moves.
• Quantum Biopharma's Accounts Payables stood at $7.5 million in 2021, then slipped by 5.36% to $7.1 million in 2022, then tumbled by 40.99% to $4.2 million in 2023, then fell by 22.41% to $3.3 million in 2024, then sank by 39.11% to $2.0 million in 2025.
• The last three Accounts Payables figures came in at $2.0 million (Q4 2025), $3.3 million (Q4 2024), and $4.2 million (Q4 2023), per Business Quant data.